AB Science completes 5 million euro capital increase

Bio-pharmaceutical company AB Science announced the completion of its recent capital increase, raising 5 million euros. The company stated that the funds raised will be used to support the advancement and financing of its clinical studies.

The capital increase was carried out through a private placement, a method where new shares are issued to a select group of investors rather than through a public offering. This approach can often provide a quicker and more flexible route to securing capital.

AB Science focuses on developing next-generation therapeutics for various diseases, including oncology and neurodegenerative disorders. The company's drug development pipeline includes several promising compounds, with masitinib being a key focus. Masitinib is currently undergoing multiple clinical trials across different indications.

The capital raised will enable AB Science to progress its drug candidates through critical development stages, potentially accelerating their path to market. Securing such funding is essential for the lengthy and costly process of drug development.